Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal-Reference-Cited by-同舟云学术

Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Published:2022-10-07 Issue:1 Volume:30 Page:266-282
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Meisel Andreas¹^ORCID,Baggi Fulvio²,Behin Anthony³,Evoli Amelia⁴,Kostera‐Pruszczyk Anna⁵,Mantegazza Renato²,Morales Raul Juntas⁶,Punga Anna Rostedt⁷^ORCID,Sacconi Sabrina⁸,Schroeter Michael⁹,Verschuuren Jan¹⁰^ORCID,Crathorne Louise¹¹,Holmes Kris¹¹,Leite Maria‐Isabel¹²

Affiliation:

1. Department of Neurology, Integrated Myasthenia Gravis Center, NeuroCure Clinical Research Center Charité Universitätsmedizin Berlin Berlin Germany

2. Neuroimmunology and Neuromuscular Diseases Unit Scientific Institute for Research and Health Care Foundation Carlo Besta Neurological Institute Milan Italy

3. Department of Neuromyology, Pitié‐Salpêtrière Hospital Public Hospital Network of Paris, Institute of Myology Paris France

4. Catholic University of the Sacred Heart and Agostino Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care Rome Italy

5. Department of Neurology Medical University of Warsaw Warsaw Poland

6. Neurology Department Vall d'Hebron University Hospital Barcelona Spain

7. Department of Medical Science, Clinical Neurophysiology Uppsala University Uppsala Sweden

8. Nice University Hospital Center Nice France

9. Department of Neurology University Hospital Cologne Cologne Germany

10. Neurology Leiden University Medical Center Leiden the Netherlands

11. Prescript Communications Letchworth UK

12. Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK

Funder

Argenx

Publisher

Wiley